Company / Revenue
Biogen Revenue History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue
$9.9B
FY2025
5-year range
$9.7B / $11.0B
FY2021-FY2025
Trend
+2.2%
vs FY2024
Sector context
#15 of 153
Health Care
What the data says
Among 153 Health Care companies, Biogen is in the top 10% for revenue. Revenue returned to growth in FY2025 after 5 years of decline, reaching $9.9B.
Based on SEC 10-K filings.
$9.9B in FY2025 with a 5-year CAGR of -6.0%. Top quartile in the Health Care sector.
Remained stable around $9.9B over the past 2 years.
Health Care sector context is included.
Revenue over time
Growth rates
- 3-Year CAGR
- -0.9%
- 5-Year CAGR
- -6.0%
- 10-Year CAGR
- -
Sector benchmark
Top 10% in Health CareTop 10% of 153This company $9.9B Sector average $4.5B
▼
+118.9% above sector average
Key checks
Key Insights
- 5-year CAGR of -6.0%, indicating a declining trend.
- In FY2025, revenue increased 2.2% year-over-year.
- Ranks #15 out of 153 companies in the Health Care sector.
- Peak revenue was recorded in FY2019.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $9.9B | +2.2% |
| FY2024 | $9.7B | -1.6% |
| FY2023 | $9.8B | -3.3% |
| FY2022 | $10.2B | -7.4% |
| FY2021 | $11.0B | -18.3% |
| FY2020 | $13.4B | -6.5% |
| FY2019 | $14.4B | +6.9% |
| FY2018 | $13.5B | +9.6% |
| FY2017 | $12.3B | +7.2% |
| FY2016 | $11.4B | +6.4% |
As of FY2025 · SEC 10-K · Updated Mar 3, 2026